Introduction: In a previously published study,
INTRODUCTION
Hypoglycemia is a common problem in patients with type 2 diabetes mellitus (T2DM), occurring most frequently with anti-hyperglycemic treatments increasing insulin levels independently of the blood glucose level, such as oral insulin secretagogues [sulfonylureas [SUs] and glinides] and exogenous insulin.
Hypoglycemia is associated with multiple adverse consequences that may, in some cases, counterbalance the benefit of strict glycemic control. Importantly, hypoglycemia is recognized as a major limiting factor for achieving intensive glycemic control in people with T2DM [1, 2] and makes clinicians less likely to implement glycemic targets [3] . Hypoglycemia is also often associated with weight gain due to decreased adherence to diet with ''defensive eating'' to prevent and/or correct hypoglycemia [4] . Furthermore, severe hypoglycemic events have been associated with an increased risk of cardiovascular complications and death [5, 6] . Lastly, episodes of hypoglycemia reduce adherence to therapy as well as quality of life [7] and lead to increased medical costs [8] .
Unlike indiscriminate insulin secretagogues, such as SUs and glinides, dipeptidyl peptidase-4 (DPP-4) inhibitors regulate glucose homeostasis in a glucose-dependent manner and are, consequently, associated with a low risk of hypoglycemia [9] . In addition to the glucosedependent secretion of insulin and glucagon common to all incretin-based therapies, preservation of glucagon counter-regulation to hypoglycemia has been specifically shown for the DPP-4 inhibitor vildagliptin in several mechanistic studies and is likely a glucosedependent insulinotropic polypeptidemediated effect [9] [10] [11] [12] .
Clinically, the risk of hypoglycemia was compared between vildagliptin and the SU glimepiride as add-on therapy to metformin in a large, randomized, double-blind study evaluating patients with well-controlled T2DM, but not having reached target, thus being at increased risk for hypoglycemia with additional glucose-lowering therapy [13, 14] . In this study, patients treated with metformin (*1,900 mg/ day) and a mean baseline glycated hemoglobin (HbA 1c ) of 7.3% were randomized to receive either vildagliptin (50 mg twice daily [bid]) or glimepiride (titrated up to 6 mg/day), with data analyzed after 1 year (interim analysis; n = 2,789) [13] and 2 years (n = 3,118) [14] .
While the efficacy was comparable between the two treatment arms--non-inferiority established at both timepoints--vildagliptin was associated with significant reductions in the frequency and severity of hypoglycemia. 
METHODS

Patients and Study Design
Data from the aforementioned and previously published, multicenter, randomized, doubleblind study comparing vildagliptin and glimepiride were used for this analysis [13, 14] .
In this study, patients with T2DM on stable treatment with metformin and HbA 1c of 6.5-8.5% were randomized 1:1 to receive vildagliptin 50 mg bid or glimepiride for 104 weeks. Glimepiride was started at a dose of 2 mg/day and could be up-titrated to a maximum of 6 mg/day.
Assessments
Hypoglycemia was defined as symptoms suggestive of low blood glucose confirmed by self-monitored blood glucose (SMBG) measurement \3.1 mmol/L plasma glucose equivalent. HbA 1c was measured regularly in the study and analyzed by a central laboratory (Covance Central Laboratory Services).
Data Analysis
The total number of patients and demography/ baseline characteristics are presented for the vildagliptin group, the glimepiride 2 mg/day, 6 mg/day and 'other' subgroups, and the overall glimepiride group for the intent-to-treat (ITT) population.
The glimepiride subgroups were defined as follows: the 2 mg/day subgroup included all patients who remained on glimepiride 2 mg/ day throughout their entire study duration; the 6 mg/day subgroup included all patients who were either up-titrated to 6 mg/day by week 16 latest and subsequently stayed on this dose level throughout the remainder of their study duration or discontinued up to week 16 with 6 mg/day as their last dose; and the 'other' subgroup consisted of all remaining glimepiride-treated patients.
The reported post hoc analysis was done in the ITT population using discrete event-time modeling [15] , following the approach in a recently published paper [16] . Hypoglycemic risk was modeled as a function of time and last- While all data over the entire study duration were used in the modeling, it was chosen to predict the hypoglycemia risk for week 24 as the minimum duration of most standard clinical trials is 24 weeks and it falls into the main period where the SU was somewhat more efficacious than vildagliptin [13] . In addition, this time point ensured a more robust assessment compared with the later stages of the study when an increasing number of discontinuations occurred.
Mean changes from baseline in HbA 1c at week 24 in the vildagliptin group, the different glimepiride subgroups and the overall glimepiride group were analyzed using last observation carried forward in the ITT population.
Within-group comparisons (endpoint vs. baseline) were made using one sample t test at a significance level of 0.05.
Ethics and Good Clinical Practice
All study participants provided written informed consent. The protocol was approved by the independent ethics committee/institutional review board at each study site or country. The study was conducted using good clinical practice and in accordance with the Declaration of Helsinki. 
RESULTS
Demography
Changes in HbA 1c
While the hypoglycemia analyses were adjusted for last-measured HbA 1c , for completeness, changes in HbA 1c were also evaluated. were assessed at week 24. In each group, a highly significant mean change in HbA 1c from baseline to week 24 was observed. The decreases in HbA 1c were -0.5 ± 0.02% (baseline 7.3%) in the vildagliptin 50 mg bid group, -0.6 ± 0.03% (baseline 7.0%) in the glimepiride 2 mg/day subgroup, -0.7 ± 0.03% (baseline 7.5%) in the glimepiride 6 mg/day subgroup, -0.7 ± 0.03% 
DISCUSSION
In a previously published study (mean HbA 1c
7.3%), vildagliptin (50 mg bid) showed a markedly reduced risk of hypoglycemia compared with glimepiride as add-on therapy to metformin at similar efficacy [13, 14] .
However, since glimepiride was titrated from a starting dose of 2 mg/day to a maximum dose of 6 mg/day, one limitation of the trial was the perception that the SU dose was titrated to too high doses and the hypoglycemia difference was driven by the highest glimepiride dose of 6 mg/day. The present analysis, however, clearly showed a substantially lower risk of confirmed hypoglycemia with vildagliptin when compared with low-dose (2 mg/day)
glimepiride. In addition, while all glimepiride subgroups showed a higher risk than the vildagliptin group, among the glimepiride groups the hypoglycemia risk was, against common perception, more pronounced in the glimepiride 2 mg/day subgroup than in the glimepiride 6 mg/day subgroup. Thus, the previously reported hypoglycemia results were not driven by high doses of glimepiride and an inverse relationship between the glimepiride dose and hypoglycemia risk was observed.
An additional limitation of the original study concerned the possibility that differences in HbA 1c reductions/levels of HbA 1c in particular during the initial 24 weeks of the study, where glimepiride was somewhat more efficacious than vildagliptin [13] [19] . In patients with more residual b-cell sensitivity to glucose on top of the SU-induced glucose-independent insulin secretion, there is a faster postprandial b-cell response to increase insulin secretion, followed by a faster b-cell response to reduce insulin secretion when glucose levels fall [20, 21] . Thus, patients, who have lost much of their ability to secrete both insulin and glucagon in a glucosesensitive manner, can be expected to be more susceptible to hypoglycemia induced by medications that stimulate insulin secretion in a glucose-independent manner. Consequently, such patients would have been more likely to have their glimepiride dose restricted to the lowest dose level of 2 mg/day in the study underlying the present analysis and even at this dose they would still have a higher risk of hypoglycemia compared with other patients with more residual glucose sensitivity. The latter patients would consequently also be more likely to tolerate high doses of SUs, which could provide an explanation for the lower hypoglycemia risk observed in the 6 mg/ day subgroup compared with the 2 mg/day subgroup in the present analysis. Interestingly, a similar observation was previously made in a double-blind study comparing gliclazide modified release (MR; titrated from 30 mg/day to a maximum of 120 mg/day) and glimepiride (titrated from 1 mg/day to a maximum of 6 mg/ day) [22] , suggesting that this could be a general finding with SUs. In both treatment groups, most hypoglycemic events occurred at the two lowest treatment doses (representing *51% of the study population); of 22 events with gliclazide MR, there were 13 and 2 events with the 30 mg and 60 mg dose, respectively, and of 56 events with glimepiride, there were 21 and 27 events with the 1 mg and 2 mg doses, respectively [22] . While patients who are less susceptible to hypoglycemia under SU treatment obviously exist, a clear limitation in clinical practice is that it is not possible to predict which patients are more or less sensitive, unless they are actually exposed to SU treatment and potential hypoglycemia to determine their hypoglycemia risk. In addition, while some patients may start with a lower risk of hypoglycemia with SUs, it is not clear what will happen over time as T2DM
progresses and islet cell function further deteriorates.
In contrast to the SUs that stimulate insulin secretion in a glucose-independent manner, increase insulin capacity even at low glucose concentrations [23, 24] and can significantly impair glucagon counter-regulation (as shown for both tolbutamide and glibenclamide) [25, 26] , DPP-4 inhibitors, such as vildagliptin, have been shown to stimulate insulin secretion and inhibit glucagon secretion in a glucosedependent manner [9] . In addition, at hypoglycemic levels, preserved glucagon counter-regulation has been explicitly demonstrated for vildagliptin in several studies and patient groups [10, 11, 27] . These effects underlie the low propensity of vildagliptin to cause hypoglycemia, even at low levels of glycemia and across different patient groups and disease states [9, 28, 29] .
